Our lipidomics analysis revealed that ZDHHC2 knockdown significantly altered the lipid metabolite composition in prostate cancer cells, providing compelling evidence for the pivotal role of ZDHHC2 in mediating enzalutamide resistance through lipid metabolic reprogramming (Figure 3E; Figure S4B,C, Supporting Information). This evidence concerns the gene ZDHHC2 and Familial prostate cancer.